KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Synaptics (SYNA) Cash & Equivalents (2016 - 2025)

Synaptics' Cash & Equivalents history spans 17 years, with the latest figure at $437.4 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents fell 26.62% year-over-year to $437.4 million; the TTM value through Dec 2025 reached $437.4 million, down 26.62%, while the annual FY2025 figure was $391.5 million, 55.35% down from the prior year.
  • Cash & Equivalents reached $437.4 million in Q4 2025 per SYNA's latest filing, down from $459.9 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $924.7 million in Q2 2023 to a low of $158.6 million in Q1 2022.
  • Average Cash & Equivalents over 5 years is $669.3 million, with a median of $810.0 million recorded in 2022.
  • Peak YoY movement for Cash & Equivalents: plummeted 79.03% in 2022, then skyrocketed 466.2% in 2023.
  • A 5-year view of Cash & Equivalents shows it stood at $502.8 million in 2021, then skyrocketed by 62.85% to $818.8 million in 2022, then rose by 3.33% to $846.1 million in 2023, then fell by 29.55% to $596.1 million in 2024, then dropped by 26.62% to $437.4 million in 2025.
  • Per Business Quant, the three most recent readings for SYNA's Cash & Equivalents are $437.4 million (Q4 2025), $459.9 million (Q3 2025), and $391.5 million (Q2 2025).